DOCSLIB.ORG

Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM) SOCIETY STATEMENT Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM) Stephanie Both, MD,1 Michal Lew-Starowicz, MD, PhD,2 Mijal Luria, MD,3 Gideon Sartorius, MD,4,5 Elisa Maseroli, MD,6 Francesca Tripodi, PsyD,7 Lior Lowenstein, MD,8,9 Rossella E. Nappi, MD, PhD,10 Giovanni Corona, MD, PhD,11 Yacov Reisman, MD, PhD,12 and Linda Vignozzi, MD, PhD6 ABSTRACT Introduction: Hormonal contraception is available worldwide in many different forms. Fear of side effects and health concerns are among the main reasons for not using contraceptives or discontinuing their use. Although the safety and efficacy of contraceptives have been extensively examined, little is known about their impact on female sexual function, and the evidence on the topic is controversial. Aim: To review the available evidence about the effects of hormonal contraceptives on female sexuality in order to provide a position statement and clinical practice recommendations on behalf of the European Society of Sexual Medicine. Methods: A comprehensive review of the literature was performed. Main Outcome Measure: Several aspects of female sexuality have been investigated, including desire, orgasmic function, lubrication and vulvovaginal symptoms, pelvic floor and urological symptoms, partner preference, and relationship and sexual satisfaction. For each topic, data were analyzed according to the different types of hormonal contraceptives (combined estrogen-progestin methods, progestin-only methods, and oral or non-oral options). Results: Recommendations according to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence criteria and specific statements on this topic, summarizing the European Society of Sexual Medicine position, were developed. Clinical Implications: There is not enough evidence to draw a clear algorithm for the management of hormonal contraception-induced sexual dysfunction, and further studies are warranted before conclusions can be drawn. A careful baseline psychological, sexual, and relational assessment is necessary for the health care provider to evaluate eventual effects of hormonal contraceptives at follow-up. Strengths & Limitations: All studies have been evaluated by a panel of experts who have provided recom- mendations for clinical practice. Conclusion: The effects of hormonal contraceptives on sexual function have not been well studied and remain controversial. Available evidence indicates that a minority of women experience a change in sexual functioning with regard to general sexual response, desire, lubrication, orgasm, and relationship satisfaction. The patho- physiological mechanisms leading to reported sexual difficulties such as reduced desire and vulvovaginal atrophy remain unclear. Insufficient evidence is available on the correlation between hormonal contraceptives and pelvic Received June 10, 2019. Accepted August 2, 2019. 8Department of Obstetrics and Gynecology, Rambam Health Care Campus, 1Outpatient Clinic of Psychosomatic Gynecology and Sexology, Leiden Haifa, Israel; University Medical Centre, Leiden, the Netherlands; 9Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; 2Department of Psychiatry, Centre of Postgraduate Medical Education, 10Research Center for Reproductive Medicine, Gynecological Endocrinology Warsaw, Poland; and Menopause, Obstetrics and Gynecology Unit, IRCCS S. Matteo 3Center for Sexual Health, Department of Obstetrics and Gynecology, Foundation, Department of Clinical, Surgical, Diagnostic and Paediatric Hadassah University Hospital, Jerusalem, Israel; Sciences, University of Pavia, Pavia, Italy; 11 4Department of Obstetrics and Gynecology, University Hospital, Basel, Endocrinology Unit, Medical Department, Azienda Usl di Bologna, Switzerland; Maggiore-Bellaria Hospital, Bologna, Italy; 12 5Fertisuisse, Olten and Basel, Switzerland; Ziekenhuis Amstelland, Department of Urology, Amsterdam, the Netherlands 6Andrology, Women’s Endocrinology and Gender Incongruence Unit, ª Department of Experimental and Clinical Biomedical Sciences “Mario Copyright 2019, International Society for Sexual Medicine. Published by Serio,” University of Florence, Florence, Italy; Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.jsxm.2019.08.005 7Institute of Clinical Sexology, Rome, Italy; J Sex Med 2019;16:1681e1695 1681 1682 Both et al floor function and urological symptoms. Both S, Lew-Starowicz M, Luria M, et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). J Sex Med 2019;16:1681e1695. Copyright Ó 2019, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved. Key Words: Hormonal Contraception; Female Sexual Dysfunction; Sexual Desire; Vulvovaginal Atrophy; Oral Contraceptives; Intrauterine Device INTRODUCTION in order to provide a position statement and recommendations The development of modern forms of contraception had a for clinical practice on behalf of the European Society of Sexual major social, economic, and political impact by empowering Medicine. women to take greater control over family planning. In partic- ular, development of the contraceptive pill and the “sexual rev- METHODS olution” that followed broadened the availability of A comprehensive search conducted on the main medical contraception in industrialized countries and led to the separa- database included studies up to July 30, 2018. The statements tion of sexuality from procreation. This development changed were internally discussed, and levels of evidence were provided our perspectives on sex and the values linked to sexuality beyond according to the Oxford 2011 Levels of Evidence criteria reproduction, such as emotional and physical pleasure, intimacy, (https://www.cebm.net/2009/06/oxford-centre-evidence-based- and bonding. Within the last decades, an increasing variety of medicine-levels-evidence-march-2009); moreover, the quality of contraceptive options have been developed, and women can now evidence was graded applying the Oxford Centre for Evidence- select the most appropriate method for their individual situa- Based Medicine recommendations. tions, as needs and preferences change from woman to woman across the reproductive life span. A skilled approach that includes shared decision making in the selection of optimal contraceptive RESULTS methods not only improves patient satisfaction but also might Hormonal Contraceptives and Sexual Function: fi optimize contraceptive ef cacy by fostering correct use of a Potential Mechanisms of Action 1 contraceptive agent. Statement #1. Hormonal contraceptives can positively affect There is a huge discrepancy among countries in the use of sexuality by different means, including (i) overcoming fear of modern methods of contraception, including barrier methods, unwanted pregnancy during sexual activity, (ii) resolution of sterilization, injections, implants, intrauterine devices (IUDs), painful or troublesome gynecologic disorders such as endome- and oral contraceptives. Rates vary from 1.7% in South Sudan to triosis and dysmenorrhea, and (iii) reduction of body image 81.6% in Finland, with the majority of industrialized countries concerns with an increase in self-esteem for women with clinical having rates of use of about 60e75% in women of reproductive hyperandrogenism (eg, acne, hirsutism) (Level 4; Grade C). e 2 age (15 49 years) who are married or in a stable relationship. Statement #2. All available combined HCs reduce androgen Among hormonal contraceptives (HCs), the most commonly levels regardless of estrogen dosage and progestin type (Level 2; used in European countries are short-acting reversible contra- Grade B). ceptives, including combined oral contraceptives (COCs), the Statement #3. Combined oral contraceptives, transdermal patch, and the vaginal ring, followed by long-acting reversible patches, and vaginal rings showed a similar effect in increasing contraceptives, such as levonorgestrel (LNG) or copper IUDs sex hormone binding globulin (SHBG) levels and in reducing and etonogestrel implants.2 androgens levels (Level 2; Grade B). Despite good health education and the availability of contra- ceptives, it is estimated that around 34% and 54% of pregnan- Evidence cies in Western and Eastern Europe, respectively, are currently 3 HCs can positively affect sexuality by different means, unintended. Women who neither desire pregnancy nor use including (i) overcoming fear of unwanted pregnancy during contraception report that a fear of side effects and health con- sexual activity; (ii) resolution of painful or troublesome gyne- cerns are among the main reasons for not using them or dis- 4 cologic disorders, such as endometriosis, dysmenorrhea, menor- continuing their use. In the last decades, extensive literature has rhagia, and menometrorrhagia; and (iii) reduction of body image fi examined the safety and ef cacy of contraceptives, but surpris- concerns with an increase in self-esteem for women with clinical ingly little is known about the impact of HCs on female sexual hyperandrogenism (eg, acne, hirsutism).5 On the other hand, function, and available evidence on the topic is controversial. concerns about the negative sexual impact of HCs have been The aim of the present study is to review the available evidence expressed ever since they have become commercially available, about the effects of hormonal contraceptives on female sexuality with reports of detrimental effects on desire, arousal, lubrication,
Load more

Recommended publications
  • Physiology of Female Sexual Function and Dysfunction
    International Journal of Impotence Research (2005) 17, S44–S51 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Physiology of female sexual function and dysfunction JR Berman1* 1Director Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, Beverly Hills, California, USA Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30–50% of American women. While there are emotional and relational elements to female sexual function and response, female sexual dysfunction can occur secondary to medical problems and have an organic basis. This paper addresses anatomy and physiology of normal female sexual function as well as the pathophysiology of female sexual dysfunction. Although the female sexual response is inherently difficult to evaluate in the clinical setting, a variety of instruments have been developed for assessing subjective measures of sexual arousal and function. Objective measurements used in conjunction with the subjective assessment help diagnose potential physiologic/organic abnormal- ities. Therapeutic options for the treatment of female sexual dysfunction, including hormonal, and pharmacological, are also addressed. International Journal of Impotence Research (2005) 17, S44–S51. doi:10.1038/sj.ijir.3901428 Keywords: female sexual dysfunction; anatomy; physiology; pathophysiology; evaluation; treatment Incidence of female sexual dysfunction updated the definitions and classifications based upon current research and clinical practice.
    [Show full text]
  • Contraception: Choosing the Right Method for You
    Contraception: Choosing the Right Method for You Megan Sax, MD and James L. Whiteside, MD What’s available? Choosing a method of contraception can be overwhelming. The most commonly used methods of reversible contraception in the United States are: hormonal methods the intrauterine device (IUD) the implant barrier methods (e.g. male condom)1 Friends, family, and the Internet are full of stories of failed contraception or bad reactions and these stories can have a big influence that doesn’t always line up with the facts.2 However, knowing these facts is critical to figuring out what type will work best for you. Highly Effective Contraception The best place to start in choosing your contraception is to determine when, if ever, you are planning on starting a family. If you do not wish to become pregnant in the next year, a Long-Acting Reversible Contraceptive (LARC) device may be a good option. LARCs include an implant placed under the skin of the upper, inner arm (brand name Nexplanon) and the IUD. IUDs are placed inside the uterus (see Figure 1). They use copper (brand name ParaGard) or hormones (brand names: Mirena, Lilleta, Skyla, Kyleena) to stop a pregnancy from happening. LARCs are the most effective reversible form of contraception. Less than 1% of users experience unintended pregnancy during the first year of use.3 Currently, the implant Nexplanon is effective for 3 years. The hormonal IUD may be used for 3 to 5 years, depending on the brand. The copper IUD works for 10 years. These devices are inserted and removed by a medical care provider.
    [Show full text]
  • Selectively Increases Vaginal Blood Flow in Anesthetized Rats
    International Journal of Impotence Research (2003) 15, 461–464 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Short communication Topical administration of a novel nitric oxide donor, linear polyethylenimine-nitric oxide/nucleophile adduct (DS1), selectively increases vaginal blood flow in anesthetized rats P Pacher1,2*, JG Mabley1, L Liaudet1, OV Evgenov1, GJ Southan1, GE Abdelkarim1, C Szabo´ 1 and AL Salzman1 1Inotek Pharmaceuticals Corporation, Beverly, Massachusetts, USA The aim of the present study was to test the effects of a topical administration of a novel nitric oxide donor, linear polyethylenimine-nitric oxide/nucleophile adduct (DS1), on vaginal blood flow and hemodynamics in rats. Laser Doppler flowmetry was used to measure blood flow changes following topical application of DS1 (0.3 or 1.5 mg in 0.15 ml saline) into the vagina of anesthetized Wistar rats. In vivo hemodynamic parameters were measured with Millar-tip-catheter placed in the left ventricle. DS1 (1.5 mg) increased vaginal blood flow by 191 7 24, 226 7 22 and 166 7 23% of the baseline value (at 5, 15 and 30 min, respectively, after application) without affecting systemic blood pressure, heart rate and cardiac function. The increased vaginal blood flow following DS1 application returned to baseline between 45 and 60 min. Thus, topical application of nitric oxide donors such as DS1 may be useful for the treatment of female sexual dysfunction that develops due to an impairment of local blood flow supply to the vaginal tissue. International Journal of Impotence Research (2003) 15, 461–464.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Birth Cont R Ol Fact Sheet
    VAGINAL RING FACT SHEET What is the Vaginal Ring (Nuvaring®)? The Vaginal Ring is a clear, flexible, thin, plastic ring that you place in the vagina where it stays for one cycle providing a continuous low dose of 2 hormones (estrogen and progestin). It prevents pregnancy by stopping the release of an egg (ovulation), thickening the cervical fluid, and changing the lining of the uterus. How effective is the Vaginal Ring? The ring is a very effective method of birth control. The ring is about 93% effective at preventing pregnancy in typical use, which means that around 7 out of 100 people who use it as their only form of birth control will get pregnant in one year. With consistent and correct use as described in this fact sheet, it can be over 99% effective. How can I get the Vaginal Ring? You can visit a clinic to get the ring or a prescription for it and talk with a healthcare provider about whether the ring is right for you. Advantages of the Vaginal Ring Disadvantages of the Vaginal Ring Periods may be more predictable/regular and lighter Must remember to remove and replace the ring once a Less period cramping month Decreased symptoms of Premenstrual Syndrome Some users may experience mild side effects such as: (PMS) and perimenopause spotting, nausea, breast tenderness, headaches, or Can be used to skip or shorten your periods dizziness (usually these improve in the first few months Less anemia/iron deficiency caused by heavy periods of use) Does not affect your ability to get pregnant in the Possibility of high blood pressure
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Hormonal Iuds Are Small ‘T- Shaped’ Plastic Devices That Are Inserted Into the Uterus (Womb)
    HORMONAL INTRAUTERINE DEVICES (IUDs) – (Mirena and Kyleena) What are the hormonal intrauterine devices (IUDs)? The hormonal IUDs are small ‘T- shaped’ plastic devices that are inserted into the uterus (womb). The hormonal IUDs contains progestogen. This is a synthetic version of the hormone progesterone made naturally by the ovaries. The hormonal IUDs have a coating (membrane) that controls the slow release of progestogen into the uterus. There are two different hormonal IUDs available in Australia. They are sold as Mirena and Kyleena. How effective are the hormonal IUDs? The hormonal IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 years. They can be used for contraception until 55 years of age if inserted when you are 45 years of age or older. How does the hormonal IUD work? IUDs affect the way sperm move and survive in the uterus (womb), stopping sperm from meeting and fertilising an egg. IUDs can also change the lining of the uterus, making it difficult for a fertilised egg to stick to the lining to start a pregnancy. The hormonal IUDs also work by thickening the fluid around the cervix (opening to the uterus/womb). This helps to prevent sperm from entering. Sometimes the hormonal IUDs can also stop the ovaries from releasing an egg. What are differences between Mirena and Kyleena hormonal IUDs? Both Mirena and Kyleena are very effective methods of contraception that last for up to 5 years. Mirena is 99.9% effective and Kyleena is 99.7% effective. Mirena may be used until 55 years of age if inserted when you are 45 years of age or older, whereas Kyleena needs to be replaced every 5 years for all ages.
    [Show full text]
  • The Clinical and Haematological Effects of Hormonal Contraception on Women with Sickle Cell Disease
    THE CLINICAL AND HAEMATOLOGICAL EFFECTS OF HORMONAL CONTRACEPTION ON WOMEN WITH SICKLE CELL DISEASE Asma Adam Eissa Institute for Women’s Health University College London Submitted in accordance with the requirements of University College London for the degree of MD (Research) 2013 I, Asma Adam Eissa, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 ABSTRACT Sickle cell disease (SCD) is known to be a prothrombotic condition; this is also true for combined hormonal contraceptives (HC), which increases the thrombotic risks in their users. Recently, Sickle Cell Trait (SCT) has been reported to carry increased risks of thrombosis Nonetheless, HC methods are efficacious and widely used while, pregnancy carries major risks for SCD women. Hence, there is a need for robust evidence about the safety or risks of HC in SCD and SCT to aid in the choice of contraceptive methods for these women. This study aimed to test the hypothesis that there are no additional clinical or haematological risks to SCD patients and women with SCT using hormonal contraceptive methods that is over and above those inherent in their SCD and SCT status. This is a multi-centre, prospective cohort study, which looked at and compared clinical complications, haemostatic and haematological markers in 68 women with SCD, 22 women with SCT and 27 similar women with normal haemoglobin. In conclusion a two year follow-up of women with SCD using Combined Oral Contraception (COC) found no incidence of Venous Thrombo Embolism (VTE) in these women and the occurrence of other clinical complications, such as sickle-cell crises, the need for blood transfusion and hospital admissions were minimal.
    [Show full text]
  • Extended USE of LARC METHODS
    y EXTENDEd USE OF COVID-19 RESPONSE LARC METHODS Overview There is research data that supports extended use for most methods of long-acting reversible contraception (LARC) available in the United States. Studies have concluded that some hormonal IUDs (Mirena, Liletta), as well as the copper IUD (Paragard) and the contraceptive implant (Nexplanon), are effective beyond their FDA-approved duration. For each LARC method, presented below is the current duration of use as approved by the FDA, as well as links to research that shows the efficacy of use past their FDA-approved duration. When counseling a patient on extended use, inform them of both the FDA-approved duration and the evidence-based duration, and explain why the official label may not represent the most up-to-date research findings. Patients can make the choice for themselves about extending use of their LARC device, particularly in times when a visit to a provider is difficult. Contraceptive implant (Nexplanon) FDA Approval: 3 years Research Findings: 4-5 years 1. Ali M, Bahamondes L, Landoulsi SB. Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling. GlobalHealth: Science and Practice. 2017;5(4):534-539. doi:10.9745/ghsp-d-17-00296. 2. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration. American Journal of Obstetrics and Gynecology. 2017;216(6):586.e1-586.e6. doi:10.1016/j.ajog.2017.01.036.
    [Show full text]
  • Long-Acting Reversible Contraception for Adolescents
    Review Article Page 1 of 11 Long-acting reversible contraception for adolescents Gina Bravata1, Dilip R. Patel1, Hatim A. Omar2 1Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA; 2Department of Pediatrics and Obstetrics and Gynecology, University of Kentucky, Kentucky Children’s Hospital, Lexington, Kentucky, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: DR Patel; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final Approval of manuscript: All authors. Correspondence to: Dilip R. Patel. Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, 1000 Oakland Drive, Kalamazoo, Michigan, USA. Email: [email protected]. Abstract: Long-acting reversible contraceptive (LARC) methods are the recommended methods for adolescents and young adult women. Etonogestrel subdermal implant, the copper intrauterine device and levonorgestrel intrauterine devices are the currently used LARC methods. LARC methods provide effective contraception by preventing fertilization; however, none has an abortifacient effect. The etonogestrel implant is the most effective method with a Pearl index of 0.05. None of the LARC methods has any adverse effect on bone mineral density. Rare safety concerns associated with intrauterine device use include device expulsion, uterine perforation, pelvic inflammatory disease, and ectopic pregnancy. Fertility resumes rapidly upon discontinuation of LARC method. A number of factors have been shown to be barriers or facilitators of LARC method use by adolescents. This article reviews clinical aspects of use for LARC methods for the primary care medical practitioner.
    [Show full text]
  • A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh
    Case Report Annals of Clinical Case Reports Published: 25 Jan, 2019 A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh Raknuzzaman1, Anis Ahmed1*, Masud Rana1, Kazi Jannat Ara1 and Dewan Md Emdadul Hoque1 1Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Bangladesh 2Department of Epidemiology and Preventive Medicine, International Centre for Diarrhoeal Disease Research, Bangladesh Abstract Cerebral Venous Sinus Thrombosis (CVST) is a rare condition and the association between norethisterone enanthate and CVST in the literature has very seldom been reported. In this case report, a 22-year-old unmarried woman of Bangladesh presented with acute onset of headache and vomiting with history of oral intake of 5 mg norethisterone thrice daily during past 2 years for menstrual disorder. She had no history of seizure, visual disturbances, and neck stiffness, imbalance of gait and weakness of any limbs, any sensory complaints or any episode of unconsciousness during the course of illness. Bilateral papilloedema was present with more marked on left eye and serum homocysteine level was high. A brain CT scan, MRI and Magnetic Resonance Venogram (MRV) revealed thrombosed anterosuperior segment of superior sagittal sinus. She was diagnosed to have CVST due to norethisterone and was treated with low molecular weight heparin, followed by Rivaroxaban, Vitamin B12, Vitamin B6 and Folic acid. She made a complete recovery after one month of intake of rivaroxaban and withdrawn of norethisterone. Keywords: Cerebral venous sinus thrombosis; Norethisterone enanthate; Hyperhomocysteinemia; OPEN ACCESS Rivaroxaban *Correspondence: Introduction Anis Ahmed, Department of Neurology, Cerebral Venous Sinuses Thrombosis (CVST) is rare type of stroke with the annual incidence Bangabandhu Sheikh Mujib Medical ranging from 0.22 to 1.57 per 100,000 populations, affecting young individuals and mostly women University, Bangladesh, Tel: [1-3].
    [Show full text]